Recent Quotes (30 days)

You have no recent quotes
chg | %

Covalon Technologies Ltd  

(Public, CVE:COV)   Watch this stock  
Find more results for COV
2.22
0.00 (0.00%)
Jul 26 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.10 - 2.22
52 week 1.14 - 2.85
Open 2.15
Vol / Avg. 11,293.00/6,633.00
Mkt cap 47.81M
P/E     -
Div/yield     -
EPS -0.10
Shares 21.34M
Beta -1.08
Inst. own     -
Aug 17, 2017
Q3 2017 Covalon Technologies Ltd Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 15, 2017
Covalon Technologies Ltd Annual Shareholders Meeting
Jun 15, 2017
Covalon Technologies Ltd Extraordinary Shareholders Meeting
May 30, 2017
Q2 2017 Covalon Technologies Ltd Earnings Call
May 29, 2017
Q2 2017 Covalon Technologies Ltd Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 7.88% -46.12%
Operating margin 7.88% -44.19%
EBITD margin - -40.61%
Return on average assets 24.95% -43.84%
Return on average equity 39.50% -72.03%
CDP Score - -

Address

1660 Tech Ave Unit 5
MISSISSAUGA, ON L4W 5S7
Canada
+1-905-5688400 (Phone)
+1-905-5685200 (Fax)

Website links

Description

Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of medical products that manage patient outcomes and save lives in the areas of wound care, infection management and surgical procedures. The Company offers platform technologies: Collagen matrix; Antimicrobial silicone adhesive and Medical coating technology. The collagen matrix platform is used to manufacture products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. The antimicrobial silicone adhesive platform is the basis for a range of pre-surgical, post surgical and vascular access products that are designed to kill any bacteria or yeast that comes into contact with the antimicrobial silicone. The coating technology is a grafting from process, which utilizes photo-polymerization to create active grafting sites.

Officers and directors

Abe Schwartz Chairman of the Board
Brian E. Pedlar President, Chief Executive Officer, Director
Danny Brannagan Chief Financial Officer
Valerio DiTizio Chief Scientific Officer
Kim Crooks Vice President - Operations
John Hands Senior Director - Global Marketing
Elinor Caplan Director
Martin C. Bernholtz Independent Director
Ian Brindle Independent Director
Joseph Cordiano Independent Director